ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data cover art

ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

Listen for free

View show details

About this listen

 Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results from the phase 2a BETTER study, which assessed the use of the anti-fibrosis agent ISTH0036 in patients with wet AMD and DME. And Diana Do, MD, sits down to review data from the LIGHTSITE IIIB study, which examined whether patients who underwent photobiomodulation therapy realized any benefit after re-administration following a 13-month washout period. Did the break in treatment lead to irreversible vision loss? Or were patients able experience a benefit after taking more than a year off? We have the answers in this episode.

What listeners say about ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.